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Objectives – To evaluate the gingival crevicular fluid (GCF) alkaline phosphatase
(ALP) activity in growing subjects in relation to the stages of individual skeletal
maturation.
Setting and Sample Population – The Department of Biomedicine, University of
Trieste. Seventy-two healthy growing subjects (45 women and 27 men; range,
7.8–17.7 years).
Materials and Methods – Double-blind, prospective, cross-sectional design.
Samples of GCF were collected from each subject at the mesial and distal sites of
both of the central incisors, in the maxilla and mandible. Skeletal maturation phase
was assessed through the cervical vertebral maturation (CVM) method. Enzymatic
activity was determined spectrophotometrically.
Results – The relationship between GCF ALP activity and CVM stages was
significant. In particular, a twofold peak in enzyme activity was seen at the CS3 and
CS4 pubertal stages, compared to the pre-pubertal stages (CS1 and CS2) and post-
pubertal stages (CS5 and CS6), at both the maxillary and mandibular sites. No
differences were seen between the maxillary and mandibular sites, or between the
sexes.
Conclusions – As an adjunct to standard methods based upon radiographic
parameters, the GCF ALP may be a candidate as a non-invasive clinical biomarker
for the identification of the pubertal growth spurt in periodontally healthy subjects
scheduled for orthodontic treatment.
Key words: alkaline phosphatase; diagnosis; gingival crevicular fluid; orthodontics;
skeletal age measurement
Introduction
Treatment timing has a significant role in the outcomes of orthopaedic
treatment of dentoskeletal disharmonies in growing patients (1–4). In
class II growing subjects, the amount of supplementary mandibular
growth induced by functional appliances appears to be significantly
greater when the functional treatment is performed during the pubertal
growth spurt (2–5). Orthopaedic treatment of patients with class III
malocclusion (6) and rapid maxillary expansion (7) also benefits from the
identification of the optimal timing to achieve maximum efficacy, which
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in these cases is at a pre-pubertal growth phase.
Therefore, the correct identification of the different
phases of skeletal maturation represents a crucial issue
in orthodontic diagnosis and treatment planning. Sev-
eral maturational indices have been proposed to eval-
uate skeletal maturity in the growing patient. Among
these indices, the most common are the radiography-
based, hand-wrist analysis (8) and the cervical vertebral
maturation (CVM) method (1). These methods are
mainly morphological, while new possibilities might be
offered by biochemical markers. Biomarkers avoid
radiographic exposure, and they represent agents that
are involved directly in bone growth and remodelling.
Gingival crevicular fluid (GCF) is a transudate, and its
molecular constituents derive mainly from serum,
although its composition also depends on the local
periodontal environment (9). In recent years, a number
of GCF constituents have been proposed as diagnostic
indicators of periodontal status, including host
enzymes (10). Among these enzymes, alkaline phos-
phatase (ALP) is essential for bone mineralization (11),
and it was one of the first enzymes to be identified in
GCF (12). More recently, GCF ALP activity has been
proposed as a diagnostic aid in periodontology (10, 13)
and orthodontics (14, 15).
Considering serum ALP increases (16) and the man-
dibular growth spurt (1) during puberty, it can be
hypothesized that increases in GCF ALP activity occur
in relation to the pubertal spurt. Therefore, the present
prospective, double-blind study was aimed at evaluat-
ing the GCF ALP activity in growing subjects in relation
to their stages of individual skeletal growth, as recorded
through the CVM method (1) to ultimately candidate
the GCF ALP activity as a non-invasive biomarker of
individual skeletal maturation in orthodontic patients.
Materials and methods
Study population and design
This study enrolled consecutive subjects seeking
orthodontic treatment who had never been treated
before. A signed informed consent was obtained from
the parents of the subjects prior to entry into the
study, and the protocol was reviewed and approved
by the Ethical Committee of the University of Trieste,
Italy. The following enrolment criteria were observed:
1) age between 7 and 18 years; 2) intermediate or late
mixed, or permanent phases of dentition; 3) good
general health with absence of any nutritional prob-
lems; 4) no use of anti-inflammatories or antibiotics
in the month preceding entry to the study; 5) probing
depth (PD) values not exceeding 4 mm for the whole
dentition and 3 mm for the anterior sextants; and 6)
full-mouth plaque score and full-mouth bleeding
score £25%.
The subjects were scheduled for enrolment at their
first clinical examination; subsequently, during a sec-
ond visit 7–10 days prior to GCF collection, they
underwent a session of professional supragingival and
subgingival scaling and also received repeated oral hy-
giene instructions. Moreover, over the days between
professional scaling and GCF collection, the subjects
were asked to rinse their mouths out twice a day with
0.012% chlorhexidine mouthwash and were not allowed
to take any anti-inflammatories or antibiotics. At the last
clinical session, when GCF was collected for ALP activity
determination, their clinical parameters were recorded
and dental panoramic radiographs and lateral cepha-
lograms were taken immediately after GCF collection.
A total of 84 subjects were screened, out of which 72
were enrolled in the study: 45 women and 27 men
(mean age, 12.1 ± 2.3; range, 7.8–17.7 years).
Appraisal of individual skeletal maturity
Appraisal of skeletal maturity was carried out through
the CVM method on lateral cephalograms. This method
comprises six stages (CS1–6) for CVM (1). Briefly, these
are defined as follows:
CS1: when the lower borders of the second, third and
fourth vertebrae (C2, C3 and C4) are flat and the bodies
of C3 and C4 are trapezoid in shape. CS1 occurs at least
2 years before the pubertal growth spurt.
CS2: when only the lower border of C2 is concave
and the bodies of C3 and C4 are trapezoid. CS2 occurs
1 year before the growth spurt.
CS3: when the lower borders of both C2 and C3 have
concavities and the bodies of C3 and C4 are either
trapezoid or rectangular horizontal in shape. CS3 marks
the ascending portion of the growth spurt.
CS4: when the lower borders of C2–C4 have con-
cavities, and the bodies of both C3 and C4 are rectan-
gular horizontal. CS4 marks the descending portion of
the growth spurt.
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CS5: when the lower borders of C2–C4 have con-
cavities and at least one of the bodies of C3 and C4 is
square. CS5 occurs 1 year after the growth spurt.
CS6: when the lower borders of C2–C4 have con-
cavities and at least one of the bodies of C3 and C4 is
rectangular vertical. CS6 occurs at least 2 years after the
growth spurt.
An experienced orthodontist (TB) who was blinded to
the GCF ALP activities assessed the skeletal maturity of
the subjects.
Clinical monitoring and GCF collection procedures
The intra-oral clinical examination was performed by a
single operator (GP) on four sites per maxillary and
mandibular central incisor (mesial, distal, medio-buccal
and medio-palatal ⁄ lingual), as previously described
(15). Briefly, the presence of supragingival plaque (PL+),
the gingival bleeding within 15 s after probing (BOP+)
and the PD were recorded. A single expert examiner (LC)
collected the clinical data in all subjects. Contamination
of the GCF was minimized by recording the PL+ before
carefully cleaning the tooth with a sterile curette, then
by collecting GCF and subgingival plaque from the
isolated area and finally by recording the PD and BOP+.
The GCF collection was performed at both the mesial
and distal sites on each of the central upper and lower
incisors as previously described (17). Briefly, #25 stan-
dardized sterile paper strips (Inline, Torino, Italy) were
inserted 1 mm into the gingival crevice and left in situ
for 60 s. The four samples from the same dental arch
were pooled, as the maxillary and mandibular samples.
The GCF samples were transferred to plastic vials and
immediately stored at )80C, until analysed.
Enzymatic activity determination
The biochemical assays were performed by a single
operator (GP) who was blinded to the CVM stages. The
four GCF samples from both the maxillary and man-
dibular sites were resuspended in 200 ll buffer con-
taining 100 mM Tris and 20 mM MgCl2 (pH 9.8 ± 0.1)
and 6 mM p-nitrophenol phosphate. The samples were
then incubated at 37C (±<0.1C fluctuations) for 2 h,
whereby the ALP in the samples hydrolyses the p-ni-
trophenyl phosphate to p-nitrophenol and inorganic
phosphate. The reactions were then stopped by adding
5 ll 3 M NaOH, and the rates of increase in absorbance
were read with a spectrophotometer at 405 nm (13).
The relevant control for each analysis consisted of the
reagent and the Tris buffer without the sample. Using
18.45 as the p-nitrophenol mM absorptivity, the
absorbance was converted into enzyme activity units
(1 unit = 1 mmol of p-nitrophenol released per minute
at 37C) and expressed as total activity in mU ⁄ sample
(18).
Data analysis
SPSS software, version 13.0 (SPSS Inc., Chicago, IL,
USA) was used to perform the statistical analyses.
Parametric methods were used only for those contin-
uous data sets that met the required assumptions
of normality of the distributions and equality of vari-
ances, tested by the Shapiro–Wilk and Levenes tests,
respectively.
The balancing of experimental groups (clustered
according to the CVM stages) by sex was tested by chi-
squared analysis. The following analyses were carried
out considering the maxillary and mandibular sites of
each patient as the statistical unit. Among the different
CVM stages, the significance of the differences in the
%PL+ and %BOP+ was assessed by a Kruskal–Wallis
test, while the significance of the difference in the
mean PD was assessed by a one-way analysis of vari-
ance. Between the maxillary and mandibular sites,
within each CVM stage, the significance of the differ-
ences in the %PL+ and %BOP+ was assessed by a Wil-
coxon rank sum test, while the significance of the dif-
ferences in the mean PD was assessed by a paired
t-test. The Kruskal–Wallis test, followed by a Tukey test,
assessed the significance of the differences in the
enzyme activities between the different CVM stages.
Finally, the subjects, considered as the statistical
units, were also clustered into three groups according
to their growth phases, as pre-pubertal (CS1 and CS2),
pubertal (CS3 and CS4) and post-pubertal (CS5 and
CS6). This clustering was used for the calculation of the
effect size (ES) coefficients (19). The ES coefficient is
the ratio of the difference between the recordings of
two different groups, i.e. GCF ALP activity of the pre-
pubertal and pubertal groups, divided by the within-
subject standard deviation (SD). Sample size of at least
20 subjects for each of these three pre-pubertal,
pubertal and post-pubertal groups was set to detect a
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minimum ES coefficient of 1.0 among them, with an
alpha set at 0.05 and a power of 0.8 (19). Moreover, the
actual ES coefficients retrieved have also been used as
indexes of potential diagnostic accuracy of the GCF
ALP activity as previously described (20). In this regard,
a threshold of 1.0 was used to assess a potential good
diagnostic accuracy (20). The Kruskal–Wallis test fol-
lowed by the Tukey test assessed the significance of the
differences in the enzyme activities between the growth
phases.
Kappa statistics testing the intra-examiner agree-
ment of the CVM appraisal showed a value above 0.90.
A p value <0.05 was used for rejection of the null
hypothesis.
Results
The age of the subjects clustered according to the CVM
stages, as shown in Table 1. Moreover, the distribution
of the sexes was similar among the groups compared
(not shown).
The pooled maxillary and mandibular %PL+ and
%BOP+ were, as medians (25th–75th percentile): 12.5
(0;25.0) and 6.25 (0;12.5), respectively. The pooled
maxillary and mandibular PD as the mean ± SD was
1.7 ± 0.3. No significant differences were seen between
the CVM stages (not shown).
The GCF ALP activities seen in the subjects clustered
according to CVM stage are shown in Table 2. The GCF
ALP activities were significantly different across the
CVM stages, for both the maxillary and mandibular sites.
About a twofold peak in GCF ALP activity was recorded
for the pubertal phases (CS3 and CS4), compared to
those of the pre-pubertal (CS1 and CS2) and post-
pubertal (CS5 and CS6) phases. At the pairwise com-
parisons, the enzymatic activities recorded for the CS4
maxillary sites and the CS3 mandibular sites were sig-
nificantly greater when compared to the corresponding
activities of CS2 (p < 0.05). Moreover, the GCF ALP
activities showed no significant differences between the
maxillary and mandibular sites within each of the CVM
stages or between the sexes (not shown).
The maxillary and mandibular pooled GCF ALP
activities clustered according the growth phases (pre-
pubertal, pubertal and post-pubertal) are shown in
Fig. 1. Statistically significant differences between the
groups were seen for all of the comparisons (p = 0.001).
The ES coefficients between the pubertal group with
respect to the pre-pubertal and post-pubertal groups
were 1.80 and 1.03, respectively.
Discussion
The present study investigated the possible relation-
ships between GCF ALP activity and skeletal matura-
tion, and it demonstrates that the pubertal growth
spurt can be detected at the level of the GCF. Therefore,
a diagnostic potential of GCF as a non-invasive tool for
Table 1. Ages of the subjects in the different groups according to
cervical vertebral maturation (CVM) stages (n = 72)
CVM stage N
Age (years)
Mean ± SD Min–max
CS1 12 9.6 ± 1.0 7.8–10.8
CS2 14 11.0 ± 1.1 8.6–13.0
CS3 11 11.0 ± 1.5 8.3–13.6
CS4 12 13.0 ± 1.7 10.8–16.5
CS5 11 13.3 ± 1.5 9.5–15.2
CS6 12 15.1 ± 1.9 11.8–17.7
N, number of subjects in each group; min, minimum age; max, maximum
age.
Table 2. Gingival crevicular fluid (GCF) alkaline phosphatase
(ALP) activities from the maxillary and mandibular sites according
to cervical vertebral maturation (CVM) stage (n = 72)
CVM stage
GCF ALP activity (mU ⁄ sample)





CS1 52.1 (31.5–77.4) 54.4 41.4 (33.1–73.4) 49.5
CS2 32.5 (24.4–70.9) 48.9 41.5 (25.6–60.9) 44.7
CS3 61.9 (48.9–157.8) 98.4 73.1 (57.4–99.0)* 87.7
CS4 97.3 (58.6–128.2)* 97.6 78.9 (47.3–92.9) 74.2
CS5 66.6 (21.9–72.0) 58.3 38.2 (19.1–49.3) 45.9
CS6 31.5 (19.1–100.8) 50.6 39.7 (18.2–66.4) 49.8
Diff. p < 0.05 p < 0.05
Statistically significant differences at the pairwise comparisons: *, with
the corresponding CS2 (p < 0.05). No significant differences were seen
between the maxillary and mandibular sites within each CVM stage.
Diff., significance of the differences between the CVM stages.
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the identification of individual skeletal maturation
stages is initially uncovered here.
As GCF ALP activity increases during periodontal
inflammation (12, 13), periodontal health is necessary
to exclude any possible unwanted sources of this en-
zyme. Herein, all of the subjects received a session of
professional oral hygiene and showed optimal peri-
odontal conditions, with very low %PL+ and %BOP+
scores and with mean PD below 2 mm. The clinical
conditions were thus similar among the subjects at the
different CVM stages, and between the maxillary and
mandibular sites within each group (not shown).
Once local tissue inflammation is excluded, and by
considering the GCF formation modalities (21), two
potential sources might be responsible for these vari-
ations in GCF ALP activity: 1) serum ALP (as a systemic
factor) and 2) maxillary ⁄ mandibular growth (as a local
skeletal factor). In more detail, the serum ALP activity,
which is the most used biochemical marker for bone
turnover, has been reported to increase at puberty and
to decrease in adulthood (16).
When the GCF ALP activities were assessed in rela-
tion to the different CVM stages, increased activities
were seen for both the maxilla and mandible at CS3
and CS4, compared to all of the other CVM stages.
These differences were statistically significant within
the maxillary and mandibular sites. However, no sig-
nificant differences were seen between the maxillary
and mandibular sites within each of the CVM stages
(Table 2). In this regard, the similar behaviours of the
GCF ALP activities of the maxillary and mandibular
sites indicate that the differential rates and timing of
the local basal bones have little influence on the GCF
enzymatic activities, which would thus be more
responsive to systemic factors. As growth areas of the
maxillary and mandibular bones are not located in
close proximity to the sampling sites, this might explain
these data. Therefore, influence from the serum ALP
can be hypothesized, even though no previous studies
have specifically correlated serum ALP activities with
CVM stages.
Interestingly, the pairwise comparisons showed sig-
nificant differences in the GCF ALP activities of the
pubertal stages (CS3 and CS4) with CS2, which, in turn,
were slightly lower and less variable when compared to
CS1 (Table 2). Although the differences between CS1
and CS2 in terms of enzymatic activities were minimal
and not significant, these data are consistent with
previous evidence relating to a minimal pre-pubertal
growth phase that precedes the growth spurt (4). The
GCF ALP activities in the post-pubertal stages (CS5 and
CS6) then decreased to levels comparable to those of
the pre-pubertal stages (CS1 and CS2). This decrease
can be explained by reduction in serum bone ALP
activity (16) during the post-pubertal periods. There-
fore, this tends to confirm that systemic growth has an
impact on GCF composition, while sex appears to have
no effects on its ALP activity.
Diagnostic potential and accuracy of GCF ALP activity as a
biomarker of the growth spurt
The maxillary and mandibular pooled GCF ALP activi-
ties showed similar levels between the two pre-pubertal
(CS1 and CS2) and the two post-pubertal (CS5 and CS6)
stages (Table 2); therefore, it appears that any diag-
nostic use of GCF ALP activity would be addressed to
the identification of the three main growth phases, pre-
pubertal, pubertal and post-pubertal, irrespective of
the maxillary or mandibular sampling sites (Fig. 1).
The clinical usefulness of a biomarker for the iden-
tification of the pubertal growth spurt is critically
dependent upon the accuracy that such a diagnostic
tool has. Therefore, a critical approach to assess the
potential of GCF ALP activity as a diagnostic aid in
orthodontics has to rely on the concept that to have
high accuracy, the measurement outcomes recorded in
two groups of subjects (i.e. pubertal vs. pre-pubertal or
post-pubertal) have to show large enough differences
Fig. 1. Pooled maxillary and mandibular gingival crevicular fluid
alkaline phosphatase activities according to growth phases and the
corresponding ES (n = 72). Data are presented as means ± SD. ES,
effect size coefficients, as indicated. Statistically significant differ-
ences at the pairwise comparisons: *, with the pre-pubertal and post-
pubertal growth phases (p = 0.001). Pre-pubertal n = 26, pubertal
n = 23, post-pubertal n = 23.
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between the groups, compared to their corresponding
variances. A statistical approach to quantify this ratio
(taking into account the size of the study populations)
is provided by the calculation of the ES coefficient (19).
A theoretical prerequisite for a diagnostic tool to be
accurate is to show an ES coefficient at least equal to
1.0 (20). In the present study, the ES retrieved between
the pubertal (CS3 and CS4) and pre-pubertal (CS1 and
CS2) or post-pubertal (CS5 and CS6) subjects was 1.80
and 1.03, respectively (Fig. 1). In this regard, the
inclusion of multiple collection sites in each of the
maxillary and mandibular sites probably contributed to
the reduction in inter-subject variability that has been
encountered when using single GCF samples (14, 15).
These data thus warrant further longitudinal studies to
define diagnostic ranges and individual curves for the
GCF ALP activity according to the skeletal maturation
phases.
Clinical implications
As shown in Table 2, the enzyme activity peak seen for
CS3 and CS4 would overlap with the mandibular
growth spurt, which has been shown mainly in skeletal
class I subjects (1, 22). In this regard, the present
sample included consecutive patients with all of the
three skeletal class patterns, which were equally dis-
tributed among the different CVM stages (not shown).
However, given the lack of differences between the
maxillary and mandibular sites, the type of sagittal
skeletal malocclusion per se is not expected to influ-
ence the GCF ALP activity. Therefore, given the tem-
poral overlap of the stature and mandibular growth
spurts (23), the GCF ALP activity would be a candidate
as a biomarker of the onset of the mandibular growth
spurt, which would have relevant diagnostic purposes
in orthopaedic treatment of class II subjects.
Finally, GCF analysis offers several advantages from a
clinical standpoint. Its sampling involves a very simple,
rapid and non-invasive procedure that can be per-
formed in a clinical setting, even in the case of multiple
GCF collections. Moreover, the ALP activity can be
determined through routine and cheap laboratory
analyses that are already available.
Conclusions
This study is the first that demonstrates an influence of
skeletal maturation on GCF composition. As an adjunct
to standard methods based upon radiographic param-
eters, GCF ALP appears to be a valid candidate as a
non-invasive biomarker of the pubertal growth spurt in
periodontally healthy subjects scheduled for ortho-
dontic treatment.
Clinical relevance
The identification of the individual skeletal matura-
tion stages is crucial for the enhancement of the
efficiency of dentofacial orthopaedic treatment. GCF
ALP activity is a candidate as a non-invasive bio-
marker of individual skeletal maturation and has
diagnostic potential for the identification of the
optimal timing for facial orthopaedic treatment of
different dentoskeletal disharmonies in growing
patients.
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